Phathom Pharmaceuticals, Inc. (PHAT) stock
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.30−0.20 (-3.64%)
Close on Nov 18, 2026Market cap $430.84MP/E –Yield –
Phathom Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Phathom Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $274.88M, up 86.8% year over year. For fiscal 2025 it was $175.11M, up 216.9% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $175.11M | +216.9% |
| FY2024 | Dec 31, 2024 | $55.25M | +8001.5% |
| FY2023 | Dec 31, 2023 | $682.00K | – |
| FY2022 | Dec 31, 2022 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $84.72M | +71.1% |
| Q2 FY2026 | Jun 30, 2026 | $74.27M | +88.0% |
| Q1 FY2026 | Mar 31, 2026 | $58.30M | +104.4% |
| Q4 FY2025 | Dec 31, 2025 | $57.58M | +94.1% |
| Q3 FY2025 | Sep 30, 2025 | $49.50M | +202.7% |
| Q2 FY2025 | Jun 30, 2025 | $39.50M | +439.4% |
| Q1 FY2025 | Mar 31, 2025 | $28.52M | +1391.6% |
| Q4 FY2024 | Dec 31, 2024 | $29.66M | +4249.6% |
| Q3 FY2024 | Sep 30, 2024 | $16.35M | – |
| Q2 FY2024 | Jun 30, 2024 | $7.32M | – |
| Q1 FY2024 | Mar 31, 2024 | $1.91M | – |
| Q4 FY2023 | Dec 31, 2023 | $682.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $0 | – |
See a number that looks wrong?